Lasmiditan

{{Short description|Chemical compound}} {{Use dmy dates|date=March 2024}} {{Drugbox | Verifiedfields = verified | verifiedrevid = 451563097 | image = Lasmiditan.svg | image_class = skin-invert-image | width = 250px | alt = | caption =

<!-- Clinical data --> | pronounce = {{IPAc-en|l|æ|z|ˈ|m|ɪ|d|ɪ|t|æ|n}}<br />{{respell|laz|MID|i|tan}} | tradename = Reyvow, Rayvow | Drugs.com = {{Drugs.com|monograph|lasmiditan-succinate}} | MedlinePlus = a620015 | DailyMedID = Lasmiditan | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth, intravenous | class = Serotonin 5-HT_1F receptor agonist; Antimigraine agent | ATC_prefix = N02 | ATC_suffix = CC08 | ATC_supplemental =

<!-- Legal status --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F--> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled--> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> | legal_UK_comment = | legal_US = Schedule V | legal_US_comment = <ref name="Reyvow FDA label" /><ref name="DEA">{{cite web | title=2020 - Placement of Lasmiditan in Schedule V | website=DEA Diversion Control Division | date=31 January 2020 | url=https://www.deadiversion.usdoj.gov/fed_regs/rules/2020/fr0131.htm | access-date=31 January 2020 | archive-date=31 January 2020 | archive-url=https://web.archive.org/web/20200131195103/https://www.deadiversion.usdoj.gov/fed_regs/rules/2020/fr0131.htm | url-status=live }}</ref> | legal_EU = Rx-only | legal_EU_comment = <ref name="Rayvow EPAR" /> | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> | legal_UN_comment = | legal_status = <!--For countries not listed above-->

<!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion =

<!-- Identifiers --> | CAS_number_Ref = {{cascite|correct|CAS}} | CAS_number = 439239-90-4 | CAS_supplemental = | PubChem = 11610526 | IUPHAR_ligand = 3928 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB11732 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 9785281 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 760I9WM792 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D10338 | ChEBI_Ref = | ChEBI = | ChEMBL_Ref = | ChEMBL = | NIAID_ChemDB = | PDB_ligand = | synonyms = COL-144; COL144; LY-573144; LY573144

<!-- Chemical data --> | IUPAC_name = 2,4,6-Trifluoro-''N''-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide | C=19 | H=18 | F=3 | N=3 | O=2 | SMILES = CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27) | StdInChI_comment = | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = XEDHVZKDSYZQBF-UHFFFAOYSA-N

<!-- Physical data --> | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }} <!-- Definition and medical uses --> '''Lasmiditan''', sold under the brand name '''Reyvow''', is a medication used to treat migraines.<ref name="Reyvow FDA label" /> It is not useful for prevention.<ref name="Reyvow FDA label" /> The drug is taken by mouth.<ref name="Reyvow FDA label" />

<!-- Side effects and mechanism --> Common side effects include sleepiness, dizziness, tiredness, and numbness.<ref name="FDA2019">{{cite press release |title=FDA approves new treatment for patients with migraine |url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine |website=U.S. Food and Drug Administration (FDA) |access-date=17 October 2019 |date=11 October 2019 | archive-url=https://web.archive.org/web/20191116075147/https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine | archive-date=16 November 2019 | url-status=dead }} {{PD-notice}}</ref><ref>{{cite web | title=Lasmiditan (Professional Patient Advice) | website=Drugs.com | date=4 June 2019 | url=https://www.drugs.com/ppa/lasmiditan.html | access-date=23 February 2020 | archive-date=27 January 2020 | archive-url=https://web.archive.org/web/20200127042427/https://www.drugs.com/ppa/lasmiditan.html | url-status=live }}</ref>

<!-- History and culture --> Lasmiditan was approved in the United States in October 2019<ref name="FDA2019"/> and became available in February 2020.<ref>{{cite press release | title=Lilly's Reyvow (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription | website=Eli Lilly and Company | date=31 January 2020 | url=https://investor.lilly.com/news-releases/news-release-details/lillys-reyvowtm-lasmiditan-c-v-first-and-only-medicine-new-class | access-date=23 February 2020 | archive-date=23 February 2020 | archive-url=https://web.archive.org/web/20200223204341/https://investor.lilly.com/news-releases/news-release-details/lillys-reyvowtm-lasmiditan-c-v-first-and-only-medicine-new-class | url-status=live }}</ref> It was developed by Eli Lilly.<ref name="FDA2019"/> The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.<ref>{{cite web | title=New Drug Therapy Approvals 2019 | website=U.S. Food and Drug Administration | date=31 December 2019 | url=https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019 | access-date=15 September 2020 | archive-date=16 September 2020 | archive-url=https://web.archive.org/web/20200916144738/https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019 | url-status=dead }}</ref> Lasmiditan is a Schedule V controlled substance in the United States.<ref name="FederalRegister2020" />

==Medical uses== Lasmiditan is used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.<ref name="Reyvow FDA label" /> It is not indicated for migraine prevention.<ref name="Reyvow FDA label" />

==Adverse effects== There is a risk of driving impairment while taking lasmiditan. People are advised not to drive or operate machinery for at least eight hours after taking lasmiditan, even if they feel well enough to do so. People who cannot follow this advice are advised not to take lasmiditan. The drug causes central nervous system (CNS) depression, including dizziness and sedation. It should be used with caution if taken in combination with alcohol or other CNS depressants.<ref name="Reyvow FDA label">{{cite web | title=Reyvow- lasmiditan tablet | website=DailyMed | date=11 October 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aea3358c-ff41-4490-9e6d-c7bf7b3de13f | access-date=15 November 2019 | archive-date=25 November 2020 | archive-url=https://web.archive.org/web/20201125230434/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aea3358c-ff41-4490-9e6d-c7bf7b3de13f | url-status=live }}</ref>

==Pharmacology== ===Mechanism of action=== {| class="wikitable floatleft" style="font-size:small;" |+ {{Nowrap|Lasmiditan activities}} |- ! Target !! Affinity (K_i, nM) |- | 5-HT_1A || 407–1,053 (K_i)<br />>10,000 ({{Abbrlink|EC₅₀|half-maximal effective concentration}})<br />16% ({{Abbrlink|E_max|maximal efficacy}}) |- | 5-HT_1B || 955–1,043 (K_i)<br />≥10,000 ({{Abbr|EC₅₀|half-maximal effective concentration}})<br />49% ({{Abbr|E_max|maximal efficacy}}) |- | 5-HT_1D || 490–1,357 (K_i)<br />229–>1,000 ({{Abbr|EC₅₀|half-maximal effective concentration}})<br />73% ({{Abbr|E_max|maximal efficacy}}) |- | 5-HT_1E || 594–1,450 (K_i)<br />676–~10,000 ({{Abbr|EC₅₀|half-maximal effective concentration}})<br />55% ({{Abbr|E_max|maximal efficacy}}) |- | 5-HT_1F || 2.2–3.1 (K_i)<br />3.7–43 ({{Abbr|EC₅₀|half-maximal effective concentration}})<br />81% ({{Abbr|E_max|maximal efficacy}}) |- | 5-HT_2A || >10,000 (K_i)<br />>10,000 ({{Abbr|EC₅₀|half-maximal effective concentration}}) |- | 5-HT_2B || 6,030 (K_i)<br />>10,000 ({{Abbr|EC₅₀|half-maximal effective concentration}}) |- | 5-HT_2C || >3,000 (K_i)<br />{{Abbr|ND|No data}} ({{Abbr|EC₅₀|half-maximal effective concentration}}) |- | 5-HT₃ || {{Abbr|ND|No data}} |- | 5-HT₄ || {{Abbr|ND|No data}} |- | 5-HT_5A || {{Abbr|ND|No data}} |- | 5-HT₆ || >4,000 |- | 5-HT₇ || >10,000 (K_i)<br />>10,000 ({{Abbr|EC₅₀|half-maximal effective concentration}}) |- | α_1A–α_1D || {{Abbr|ND|No data}} |- | α₁ || >10,000 |- | α_2A–α_2C || {{Abbr|ND|No data}} |- | α₂ || >10,000 |- | β₁, β₂ || >10,000 |- | β₃ || {{Abbr|ND|No data}} |- | D₁, D₁ || >10,000 |- | D₁–D₅ || {{Abbr|ND|No data}} |- | H₁ || >10,000 |- | H₂–H₄ || {{Abbr|ND|No data}} |- | M₁–M₅ || {{Abbr|ND|No data}} |- | mACh || >3,000 |- | I₁, I₂ || {{Abbr|ND|No data}} |- | σ₁, σ₂ || {{Abbr|ND|No data}} |- | {{Abbrlink|TAAR1|Trace amine-associated receptor 1}} || {{Abbr|ND|No data}} |- | {{Abbrlink|SERT|Serotonin transporter}} || {{Abbr|ND|No data}} |- | {{Abbrlink|NET|Norepinephrine transporter}} || {{Abbr|ND|No data}} |- | {{Abbrlink|DAT|Dopamine transporter}} || {{Abbr|ND|No data}} |- class="sortbottom" | colspan="2" style="width: 1px; background-color:var(--background-color-notice-subtle,#eaecf0); color:inherit; text-align: center;" | '''Notes:''' The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. '''Refs:''' <ref name="BindingDB">{{cite web | last=Liu | first=Tiqing | title=BindingDB BDBM50573975 COL-144::LY573144::Lasmiditan | website=BindingDB | url=https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50573975 | access-date=28 July 2025}}</ref><ref name="NelsonPhebusJohnson2010">{{cite journal | vauthors = Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC | title = Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan | journal = Cephalalgia | volume = 30 | issue = 10 | pages = 1159–1169 | date = October 2010 | pmid = 20855361 | doi = 10.1177/0333102410370873 | url = }}</ref><ref name="ReuterNeeb2012">{{cite journal | vauthors = Reuter U, Neeb L | title=Lasmiditan hydrochloride | journal=Drugs of the Future | volume=37 | issue=10 | date=2012 | issn=0377-8282 | doi=10.1358/dof.2012.037.010.1873629 | page=709 | url=http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1873629&p_IsPs=N | access-date=19 June 2025| url-access=subscription }}</ref><ref name="Rubio-BeltránLabastida-RamírezHaanes2019">{{cite journal | vauthors = Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Zanelli E, Meeus L, Danser AH, Gralinski MR, Senese PB, Johnson KW, Kovalchin J, Villalón CM, MaassenVanDenBrink A | title = Characterization of binding, functional activity, and contractile responses of the selective 5-HT_1F receptor agonist lasmiditan | journal = British Journal of Pharmacology | volume = 176 | issue = 24 | pages = 4681–4695 | date = December 2019 | pmid = 31418454 | pmc = 6965684 | doi = 10.1111/bph.14832 | quote = TABLE 1 Summary of pIC50 (negative logarithm of the molar concentration of these compounds at which 50% of the radioligand is displaced) and pKi (negative logarithm of the molar concentration of the Ki ) values of individual antimigraine drugs at 5‐HT receptors [...] TABLE 2 Summary of pEC50 values of cAMP (5‐HT1A/B/E/F and 5‐HT7), GTPγS (5‐HT1A/B/D/E/F), and IP (5‐HT2) assays of individual antimigraine drugs at 5‐HT receptors [...] }}</ref> |}

Lasmiditan is a serotonin receptor agonist that, like the unsuccessful LY-334,370, selectively binds to the 5-HT_1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT_1B and 5-HT_1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible people, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction,<ref name="Prous">{{cite web|url=http://www.prous.com/molecules/default.asp?ID=198|archive-url=https://web.archive.org/web/20110728112115/http://www.prous.com/molecules/default.asp?ID=198|url-status=dead|archive-date=28 July 2011|publisher=Prous Science|title=Molecule of the Month July 2010: Lasmiditan hydrochloride|access-date=3 August 2011}}</ref> although a 1998 review has found such side-effects to rarely occur in people taking triptans.<ref>{{cite journal | vauthors = Dahlöf CG, Mathew N | title = Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern? | journal = Cephalalgia | volume = 18 | issue = 8 | pages = 539–545 | date = October 1998 | pmid = 9827245 | doi = 10.1046/j.1468-2982.1998.1808539.x | s2cid = 30125923 }}</ref><ref name="Mutschler">{{cite book| vauthors = Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M |title= Arzneimittelwirkungen |publisher= Wissenschaftliche Verlagsgesellschaft|location=Stuttgart|date=2001|edition=8th|page=265|isbn=978-3-8047-1763-3|oclc=47700647|language=German}}</ref> The broad receptor interactions of lasmiditan have been studied.<ref name="Rubio-BeltránLabastida-RamírezHaanes2019">{{cite journal | vauthors = Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Zanelli E, Meeus L, Danser AH, Gralinski MR, Senese PB, Johnson KW, Kovalchin J, Villalón CM, MaassenVanDenBrink A | title = Characterization of binding, functional activity, and contractile responses of the selective 5-HT_1F receptor agonist lasmiditan | journal = British Journal of Pharmacology | volume = 176 | issue = 24 | pages = 4681–4695 | date = December 2019 | pmid = 31418454 | pmc = 6965684 | doi = 10.1111/bph.14832 | quote = TABLE 1 Summary of pIC50 (negative logarithm of the molar concentration of these compounds at which 50% of the radioligand is displaced) and pKi (negative logarithm of the molar concentration of the Ki ) values of individual antimigraine drugs at 5‐HT receptors [...] TABLE 2 Summary of pEC50 values of cAMP (5‐HT1A/B/E/F and 5‐HT7), GTPγS (5‐HT1A/B/D/E/F), and IP (5‐HT2) assays of individual antimigraine drugs at 5‐HT receptors [...] }}</ref><ref name="ReuterNeeb2012">{{cite journal | vauthors = Reuter U, Neeb L | title=Lasmiditan hydrochloride | journal=Drugs of the Future | volume=37 | issue=10 | date=2012 | issn=0377-8282 | doi=10.1358/dof.2012.037.010.1873629 | page=709 | url=http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1873629&p_IsPs=N | access-date=19 June 2025| url-access=subscription }}</ref>

==History== Lasmiditan was discovered by Eli Lilly and Company and was then relicensed to CoLucid Pharmaceuticals in 2006, until CoLucid was bought by Eli Lilly in 2017, to allow Eli Lilly to reacquire the drug's intellectual property.<ref>{{Cite web | url=http://www.fiercebiotech.com/biotech/lilly-buys-migraine-biotech-colucid-for-960m-and-drug-it-out-licensed | title=Lilly buys migraine biotech CoLucid, and the drug it outlicensed, for $960M | date=18 January 2017 | access-date=30 January 2017 | archive-date=25 September 2020 | archive-url=https://web.archive.org/web/20200925032246/https://www.fiercebiotech.com/biotech/lilly-buys-migraine-biotech-colucid-for-960m-and-drug-it-out-licensed | url-status=live }}</ref> The drug is protected by patents until 2031.<ref name="adisinsight">{{Cite web | url=http://adisinsight.springer.com/drugs/800028519 | title=Lasmiditan - Eli Lilly and Company - AdisInsight | access-date=30 January 2017 | archive-date=26 September 2021 | archive-url=https://web.archive.org/web/20210926081044/https://adisinsight.springer.com/drugs/800028519 | url-status=live }}</ref>

Phase II clinical trials for dose finding purposes were completed in 2007, for an intravenous form<ref name="NCT00384774">{{cite journal | title=A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine | website=ClinicalTrials.gov | date=8 November 2019 | url=https://clinicaltrials.gov/ct2/show/NCT00384774 | access-date=23 February 2020 | archive-date=23 February 2020 | archive-url=https://web.archive.org/web/20200223211109/https://clinicaltrials.gov/ct2/show/NCT00384774 | url-status=live }}</ref> and in early 2010, for an oral form.<ref name="NCT00883051">{{cite journal | title=Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment | website=ClinicalTrials.gov | date=20 December 2019 | url=https://clinicaltrials.gov/ct2/show/NCT00883051 | access-date=23 February 2020 | archive-date=23 February 2020 | archive-url=https://web.archive.org/web/20200223211107/https://clinicaltrials.gov/ct2/show/NCT00883051 | url-status=live }}</ref> Eli Lilly submitted a new drug application to the U.S. Food and Drug Administration (FDA) in November 2018.<ref name="lillyNDA2018">{{Cite press release|title=Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache|url=http://www.prnewswire.com/news-releases/lilly-submits-new-drug-application-to-the-fda-for-lasmiditan-for-acute-treatment-of-migraine-receives-breakthrough-therapy-designation-for-emgality-galcanezumab-gnlm-for-prevention-of-episodic-cluster-headache-300750141.html|publisher=Eli Lilly and Company|via=PR Newswire|date=14 November 2018|access-date=12 October 2019|archive-date=12 October 2019|archive-url=https://web.archive.org/web/20191012233854/https://www.prnewswire.com/news-releases/lilly-submits-new-drug-application-to-the-fda-for-lasmiditan-for-acute-treatment-of-migraine-receives-breakthrough-therapy-designation-for-emgality-galcanezumab-gnlm-for-prevention-of-episodic-cluster-headache-300750141.html|url-status=live}}</ref>

Three phase III clinical trials were completed. The SPARTAN trial compared placebo with 50, 100, and 200&nbsp;mg of lasmiditan.<ref>{{ClinicalTrialsGov|NCT02605174|Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine (SPARTAN)}}</ref> SAMURAI compared placebo with 100 and 200&nbsp;mg doses of lasmiditan. GLADIATOR is an open-label study that compared 100 and 200&nbsp;mg doses of lasmiditan in subjects that received the drug as part of a prior trial.<ref>{{ClinicalTrialsGov|NCT02565186|An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR)}}</ref>

Topline results from the SPARTAN trial showed that the drug induced met its primary and secondary endpoints in the trial. The primary result showed a statistically significant improvement in pain relief relative to placebo 2 hours after the first dose. The secondary result showed a statistically significantly greater percentage of subjects were free of their most bothersome symptom (MBS) compared with placebo at two hours following the first dose.<ref>{{Cite web | url=https://investor.lilly.com/releasedetail.cfm?ReleaseID=1036101 | title=Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine | access-date=5 August 2017 | archive-url=https://web.archive.org/web/20170805220425/https://investor.lilly.com/releasedetail.cfm?ReleaseID=1036101 | archive-date=5 August 2017 | url-status=dead }}</ref>

The FDA approved lasmiditan primarily based on data from two clinical trials, Trial 1 (# NCT02439320) and Trial 2 (#NCT02605174) of 4439 subjects with migraine headaches with or without aura.<ref name="FDA Snapshot" /> Trials were conducted at 224 sites in the United States, the United Kingdom, and Germany.<ref name="FDA Snapshot" />

The FDA approved the drug in October 2019.<ref name="FDA Snapshot">{{cite web | title=Drug Trials Snapshots: Reyvow | website=U.S. Food and Drug Administration (FDA) | date=11 October 2019 | url=http://www.fda.gov/drugs/drug-trials-snapshots-reyvow | access-date=26 January 2020 | archive-date=13 December 2019 | archive-url=https://web.archive.org/web/20191213231445/https://www.fda.gov/drugs/drug-trials-snapshots-reyvow | url-status=dead }} {{PD-notice}}</ref> It was placed into Schedule V in January 2020.<ref name="DEA" /><ref name="FederalRegister2020">{{cite web|title=Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V|url=https://www.federalregister.gov/documents/2020/01/31/2020-01957/schedules-of-controlled-substances-placement-of-lasmiditan-in-schedule-v|date=31 January 2020|website=Federal Register|access-date=31 January 2020|archive-date=26 March 2021|archive-url=https://web.archive.org/web/20210326211708/https://www.federalregister.gov/documents/2020/01/31/2020-01957/schedules-of-controlled-substances-placement-of-lasmiditan-in-schedule-v|url-status=live}}</ref>

==Society and culture== ===Regulatory approval=== On 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rayvow, intended for the treatment of migraine.<ref name="Rayvow: Pending EC decision" /> The applicant for this medicinal product is Eli Lilly Nederland B.V.<ref name="Rayvow: Pending EC decision">{{cite web | title=Rayvow: Pending EC decision | website=European Medicines Agency (EMA) | date=23 June 2022 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/rayvow | access-date=26 June 2022 | archive-date=26 June 2022 | archive-url=https://web.archive.org/web/20220626014346/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/rayvow | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> Rayvow was approved for medical use in the European Union in August 2022.<ref name="Rayvow EPAR">{{cite web | title=Rayvow EPAR | website=European Medicines Agency (EMA) | date=14 September 2021 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/rayvow | access-date=6 October 2022 | archive-date=6 October 2022 | archive-url=https://web.archive.org/web/20221006034723/https://www.ema.europa.eu/en/medicines/human/EPAR/rayvow | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref>{{cite web | title=Rayvow Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1587.htm | access-date=3 March 2023}}</ref>

Lasmiditan has not been approved for use in Canada. The drug sponsor in Canada, Eli Lilly Canada Inc., filed a New Drug Submission in February 2020 but cancelled the submission before a final decision was issued by Health Canada. Health Canada had completed their review of the submission and did not find any deficiencies in the data packages provided in the submission. However, Health Canada and Eli Lilly could not come to agreement on the interpretation of the cardiovascular data and how it would be worded in the product monograph. The drug sponsor cancelled their submission on 26 January 2021 before Health Canada issued a final decision.<ref name=hc2021>{{cite web|url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detailTwo.php?lang=en&linkID=RDS00789|title=Regulatory Decision Summary - Reyvow|date=23 October 2014 |publisher=Health Canada|access-date=22 June 2023}}</ref>

===Legal status=== ====United States==== Lasmiditan is a Schedule V controlled substance in the United States.<ref name="FederalRegister2020" /> This was based on lasmiditan producing reinforcing effects in a self-administration assay in rodents and increasing drug-liking scores more than placebo but less than the benzodiazepine alprazolam as well as producing euphoric mood in humans.<ref name="FederalRegister2020" /> Other effects in humans included somnolence and feeling drunk.<ref name="FederalRegister2020" /> Misuse-related adverse effects occurred at a low but significant frequency (~1%) in clinical trials.<ref name="FederalRegister2020" />

==See also== * Triptan * Alniditan

==References== {{Reflist}}

{{Antimigraine preparations}} {{Serotonin receptor modulators}} {{Portal bar | Medicine}}

Category:5-HT1F agonists Category:Benzamides Category:Disubstituted pyridines Category:Ditans Category:Drugs developed by Eli Lilly and Company Category:Fluoroarenes Category:Ketones Category:Piperidines